Humacyte Statistics

Total Valuation

Humacyte has a market cap or net worth of $157.32 million. The enterprise value is $175.28 million.

Market Cap	157.32M
Enterprise Value	175.28M

Important Dates

The next estimated earnings date is Monday, August 10, 2026, before market open.

Earnings Date	Aug 10, 2026
Ex-Dividend Date	n/a

Share Statistics

Humacyte has 222.02 million shares outstanding. The number of shares has increased by 40.60% in one year.

Current Share Class	222.02M
Shares Outstanding	222.02M
Shares Change (YoY)	+40.60%
Shares Change (QoQ)	+5.92%
Owned by Insiders (%)	4.39%
Owned by Institutions (%)	27.05%
Float	177.79M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	78.04
Forward PS	17.90
PB Ratio	13.53
P/TBV Ratio	13.53
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	86.95
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.93, with a Debt / Equity ratio of 5.72.

Current Ratio	3.93
Quick Ratio	3.03
Debt / Equity	5.72
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-10.69

Financial Efficiency

Return on equity (ROE) is -409.47% and return on invested capital (ROIC) is -71.49%.

Return on Equity (ROE)	-409.47%
Return on Assets (ROA)	-51.48%
Return on Invested Capital (ROIC)	-71.49%
Return on Capital Employed (ROCE)	-119.20%
Weighted Average Cost of Capital (WACC)	16.20%
Revenue Per Employee	$10,957
Profits Per Employee	-$517,484
Employee Count	184
Asset Turnover	0.01
Inventory Turnover	9.34

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -67.64% in the last 52 weeks. The beta is 2.46, so Humacyte's price volatility has been higher than the market average.

Beta (5Y)	2.46
52-Week Price Change	-67.64%
50-Day Moving Average	0.99
200-Day Moving Average	1.17
Relative Strength Index (RSI)	34.57
Average Volume (20 Days)	15,568,077

Short Selling Information

The latest short interest is 40.14 million, so 18.08% of the outstanding shares have been sold short.

Short Interest	40.14M
Short Previous Month	41.16M
Short % of Shares Out	18.08%
Short % of Float	22.58%
Short Ratio (days to cover)	5.75

Income Statement

In the last 12 months, Humacyte had revenue of $2.02 million and -$95.22 million in losses. Loss per share was -$0.55.

Revenue	2.02M
Gross Profit	-81.72M
Operating Income	-112.49M
Pretax Income	-97.59M
Net Income	-95.22M
EBITDA	-105.19M
EBIT	-112.49M
Loss Per Share	-$0.55

Full Income Statement

Balance Sheet

The company has $48.54 million in cash and $66.50 million in debt, giving a net cash position of -$17.96 million or -$0.08 per share.

Cash & Cash Equivalents	48.54M
Total Debt	66.50M
Net Cash	-17.96M
Net Cash Per Share	-$0.08
Equity (Book Value)	11.62M
Book Value Per Share	0.05
Working Capital	47.41M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$101.55 million and capital expenditures -$831,000, giving a free cash flow of -$102.38 million.

Operating Cash Flow	-101.55M
Capital Expenditures	-831,000
Depreciation & Amortization	7.30M
Net Borrowing	37.67M
Free Cash Flow	-102.38M
FCF Per Share	-$0.46

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-5,579.76%
Pretax Margin	-4,840.82%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Humacyte does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-40.60%
Shareholder Yield	-40.60%
Earnings Yield	-60.52%
FCF Yield	-65.07%

Analyst Forecast

The average price target for Humacyte is $2.05, which is 189.30% higher than the current price. The consensus rating is "Buy".

Price Target	$2.05
Price Target Difference	189.30%
Analyst Consensus	Buy
Analyst Count	5
Revenue Growth Forecast (3Y)	281.12%
EPS Growth Forecast (3Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Humacyte has an Altman Z-Score of -10.63 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-10.63
Piotroski F-Score	4